Patents by Inventor Sudhir Agrawal

Sudhir Agrawal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 8486908
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: July 16, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 8476416
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: December 12, 2006
    Date of Patent: July 2, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF
    Publication number: 20130142778
    Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.
    Type: Application
    Filed: March 25, 2011
    Publication date: June 6, 2013
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: SUDHIR AGRAWAL, EKAMBAR KANDIMALLA, MALLIKARJUNA PUTTA, Ireneusz Nowak, Nicola LaMonica, Weiwen Jiang, Michael Reardon, Tao Lan
  • Compositions for inhibiting gene expression and uses thereof
    Patent number: 8431544
    Abstract: The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: April 30, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Mallikarjuna Putta, Tao Lan, Lakshmi Bhagat, Daqing Wang, Dong Yu
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 8426375
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: April 23, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Immunostimulatory oligonucleotide multimers
    Patent number: 8420615
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: April 16, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 8399423
    Abstract: The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: March 19, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 8383598
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: February 26, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 8377898
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: February 19, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Synthetic agonists of TLR9
    Patent number: 8361986
    Abstract: The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: January 29, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Mallikarjuna Putta, Daqing Wang, Dong Yu, Lakshmi Bhagat, Sudhir Agrawal
  • Stabilized immune modulatory RNA (SIMRA) compounds
    Patent number: 8362233
    Abstract: The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: January 29, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Tao Lan, Daqing Wang, Lakshmi Bhagat, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 8357665
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: January 22, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
    Publication number: 20120201807
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 9, 2012
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar R. Kandimalla
  • STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS
    Publication number: 20120183530
    Abstract: The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Application
    Filed: January 27, 2012
    Publication date: July 19, 2012
    Inventors: Ekambar Kandimalla, Tao Lan, Daqing Wang, Lakshmi Bhagat, Sudhir Agrawal
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5? ends
    Patent number: 8202850
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: June 19, 2012
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Synthetic RNA-based agonists of TLR7
    Patent number: 8202974
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7.
    Type: Grant
    Filed: February 10, 2010
    Date of Patent: June 19, 2012
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Tao Lan, Ekambar Kandimalla, Daqing Wang, Sudhir Agrawal
  • Stabilized immune modulatory RNA (SIMRA) compounds
    Patent number: 8188261
    Abstract: The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: May 29, 2012
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Tao Lan, Daqing Wang, Lakshmi Bhagat, Sudhir Agrawal
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20120128699
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These TROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: November 18, 2011
    Publication date: May 24, 2012
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS
    Publication number: 20120107303
    Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
    Type: Application
    Filed: January 14, 2011
    Publication date: May 3, 2012
    Inventors: Ekambar R. Kandimalla, Sudhir Agrawal, Daqing Wang, Lakshml Bhagat, Dong Yu
  • Modulation of toll-like receptor 3 expression by antisense oligonucleotides
    Patent number: 8153605
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR3 expression and for prevention or treatment of diseases wherein modulation of TLR3 expression would be beneficial are provided.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: April 10, 2012
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal